Brooklyn Investment Group acquired a new position in Leidos Holdings, Inc. (NYSE:LDOS – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 581 shares of the aerospace company’s stock, valued at approximately $95,000.
Other hedge funds have also made changes to their positions in the company. Ballentine Partners LLC grew its position in Leidos by 3.5% in the third quarter. Ballentine Partners LLC now owns 1,822 shares of the aerospace company’s stock valued at $297,000 after acquiring an additional 62 shares in the last quarter. Key Financial Inc grew its holdings in Leidos by 6.5% during the 2nd quarter. Key Financial Inc now owns 1,141 shares of the aerospace company’s stock valued at $166,000 after purchasing an additional 70 shares in the last quarter. Asahi Life Asset Management CO. LTD. increased its stake in Leidos by 3.2% during the 3rd quarter. Asahi Life Asset Management CO. LTD. now owns 2,280 shares of the aerospace company’s stock worth $372,000 after buying an additional 70 shares during the period. Somerset Trust Co lifted its holdings in Leidos by 3.5% in the 3rd quarter. Somerset Trust Co now owns 2,429 shares of the aerospace company’s stock worth $396,000 after buying an additional 83 shares in the last quarter. Finally, Apella Capital LLC boosted its position in Leidos by 0.8% in the 3rd quarter. Apella Capital LLC now owns 11,366 shares of the aerospace company’s stock valued at $1,878,000 after buying an additional 89 shares during the last quarter. Hedge funds and other institutional investors own 76.12% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on Leidos from $175.00 to $185.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 2nd. Wells Fargo & Company dropped their price objective on Leidos from $230.00 to $205.00 and set an “overweight” rating on the stock in a report on Tuesday. Royal Bank of Canada increased their target price on Leidos from $145.00 to $180.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 30th. TD Cowen lifted their price target on shares of Leidos from $175.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Barclays upped their price target on shares of Leidos from $165.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $187.77.
Insider Activity at Leidos
In other Leidos news, Director Robert C. Kovarik, Jr. sold 1,047 shares of Leidos stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $184.94, for a total transaction of $193,632.18. Following the sale, the director now owns 6,408 shares of the company’s stock, valued at $1,185,095.52. The trade was a 14.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Noel B. Geer purchased 2,000 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was acquired at an average cost of $161.13 per share, with a total value of $322,260.00. Following the purchase, the director now owns 2,000 shares of the company’s stock, valued at approximately $322,260. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.96% of the stock is currently owned by insiders.
Leidos Stock Performance
Shares of LDOS stock opened at $164.02 on Thursday. The company has a market cap of $21.89 billion, a P/E ratio of 18.68, a PEG ratio of 1.10 and a beta of 0.68. The business has a 50 day moving average of $170.97 and a two-hundred day moving average of $156.62. Leidos Holdings, Inc. has a 52 week low of $105.52 and a 52 week high of $202.90. The company has a quick ratio of 1.15, a current ratio of 1.23 and a debt-to-equity ratio of 0.87.
Leidos (NYSE:LDOS – Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The aerospace company reported $2.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.97. Leidos had a return on equity of 30.31% and a net margin of 7.37%. The business had revenue of $4.19 billion during the quarter, compared to analyst estimates of $4.06 billion. During the same quarter in the previous year, the firm posted $2.03 EPS. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. As a group, analysts anticipate that Leidos Holdings, Inc. will post 10.04 EPS for the current year.
Leidos Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 16th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Monday, December 16th. This is a boost from Leidos’s previous quarterly dividend of $0.38. Leidos’s dividend payout ratio (DPR) is 17.31%.
Leidos Company Profile
Leidos Holdings, Inc, together with its subsidiaries, provides services and solutions in the defense, intelligence, civil, and health markets in the United States and internationally. The company operates through Defense Solutions, Civil, and Health segments. The Defense Solutions segment offers national security solutions and systems for air, land, sea, space, and cyberspace for the U.S.
Further Reading
- Five stocks we like better than Leidos
- How to Calculate Stock Profit
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Invest in Biotech Stocks
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- 10 Best Airline Stocks to Buy
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Leidos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leidos and related companies with MarketBeat.com's FREE daily email newsletter.